C.E.S. TABLET
Ülke: Kanada
Dil: İngilizce
Kaynak: Health Canada
Ürün özellikleri
(SPC)
23-09-2020
Bu ürün için bazı belgeler şu anda mevcut değil, müşteri hizmetlerimize bir istek gönderebilirsiniz ve bunları alır almaz size bildireceğiz.
İstek gönder.
İstek gönder.
Aktif bileşen:
CONJUGATED ESTROGENS
Mevcut itibaren:
BAUSCH HEALTH, CANADA INC.
ATC kodu:
G03CA57
INN (International Adı):
CONJUGATED ESTROGENS
Doz:
0.625MG
Farmasötik formu:
TABLET
Kompozisyon:
CONJUGATED ESTROGENS 0.625MG
Uygulama yolu:
ORAL
Paketteki üniteler:
100/1000
Reçete türü:
Prescription
Terapötik alanı:
ESTROGENS
Ürün özeti:
Active ingredient group (AIG) number: 0106442006; AHFS:
Yetkilendirme durumu:
APPROVED
Yetkilendirme tarihi:
2020-09-23
Ürün özellikleri
PRODUCT MONOGRAPH
PR
C.E.S.
Conjugated Estrogens Tablets, CSD
0.625 mg
ESTROGEN
BAUSCH HEALTH, CANADA INC.
DATE OF REVISION:
2150 St-Elzear Blvd. West
September 23, 2020
Laval, Quebec
H7L 4A8
Control No.: 242944
_Pr_
_C.E.S._
_®_
_ Product Monograph Page 2 of 33_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................12
DRUG INTERACTIONS
..................................................................................................14
DOSAGE AND ADMINISTRATION
..............................................................................16
OVERDOSAGE
................................................................................................................17
ACTION AND CLINICAL PHARMACOLOGY
............................................................18
STORAGE AND STABILITY
..........................................................................................20
SPECIAL HANDLING INSTRUCTIONS
.......................................................................20
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................21
PART II: SCIENTIFIC INFORMATION
...............................................................................22
PHARMACEUTICAL INFORMATION
..........................................................................22
CLINICAL TRIALS
..........................................................................................................24
DETAIL
Belgenin tamamını okuyun
